| Literature DB >> 26852675 |
Renata Madru1, Pontus Svenmarker2, Christian Ingvar3, Freddy Ståhlberg4,5,6, Stefan-Andersson Engels7, Linda Knutsson8, Sven-Erik Strand9,10.
Abstract
Hybrid clinical imaging is an emerging technology, which improves disease diagnosis by combining already existing technologies. With the combination of high-resolution morphological imaging, i.e., MRI/CT, and high-sensitive molecular detection offered by SPECT/PET/Optical, physicians can detect disease progression at an early stage and design patient-specific treatments. To fully exploit the possibilities of hybrid imaging a hybrid probe compatible with each imaging technology is required. Here, we present a hybrid nanoprobe for triple modality MR/SPECT/Fluorescence imaging. Our imaging agent is comprised of superparamagnetic iron oxide nanoparticles (SPIONs), labeled with (99m)Tc and an Alexa fluorophore (AF), together forming (99m)Tc-AF-SPIONs. The agent was stable in human serum, and, after subcutaneous injection in the hind paw of Wistar rats, showed to be highly specific by accumulating in the sentinel lymph node. All three modalities clearly visualized the imaging agent. Our results show that a single imaging agent can be used for hybrid imaging. The use of a single hybrid contrast agent permits simultaneous hybrid imaging and, more conventionally, allow for single modality imaging at different time points. For example, a hybrid contrast agent enables pre-operative planning, intra-operative guidance, and post-operative evaluation with the same contrast agent.Entities:
Keywords: MR; SLN; SPECT; SPION; fluorescence imaging; magnetic resonance imaging; optical
Year: 2014 PMID: 26852675 PMCID: PMC4665510 DOI: 10.3390/diagnostics4010013
Source DB: PubMed Journal: Diagnostics (Basel) ISSN: 2075-4418
Figure 1Transmission electron microscopy images of nanoparticles. (a) SPIONs in 0.9% saline buffer, pH 7 and (b) 99mTc-AF-SPIONs after incubation in human serum at room temperature. The images demonstrate that the size of the nanoparticles is not affected by the labeling procedure including both radionuclides and fluorescent dye. No aggregations of the particles have been observed after incubation of 99mTc-AF-SPIONs in human serum.
Figure 2Representative coronal MR images of white Wistar rat injected subcutaneously with 99mTc-AF-SPIONs in the right hind paw. Accumulation of the 99mTc-AF-SPIONs in SLN can clearly visualized using (a) SE and (b) GRE sequences (white arrows).
Figure 3SPECT/CT image of the same animal shown by MR in Figure 2. The arrows depict the injection site and accumulation of the 99mTc-AF-SPIONs in SLN. SPECT is less affected by attenuation compared with optical imaging, therefore, is an invaluable tool to quantify and study the biodistribution of the newly developed agent.
Figure 4Optical fluorescence image visualizing the SLN. High signal to background ratio is demonstrated which encourage for possible translation of this approach to clinical applications.
Figure 5Intraoperative identification of the SLN using 99mTc-AF-SPIONs. (a) Similar to the clinical procedure using blue dye, 99mTc-AF-SPIONs stain the SLN green, which makes it easy to be identified during surgery. (b) The reference node from the collateral side of the animal. (c) The resected SLN.
Figure 6Biodistribution of 99mTc-AF-SPIONs in two white Wistar rats, 5 h post injection.
Figure 7Microscopy images of a cryosectioned SLN. (a) Coronal section (20 µm) of a half SLN indicating the microdistribution of the nanoparticles within the SLN. The blue structures are cell nucleus and the red light is emitted from the 99mTc-AF-SPIONs. The nanoparticles accumulate in the cortex and within the medullary sinuses. (b) Image visualizing the cortex of the SLN and indicating that the nanoparticles are mostly located extracellularly in comparison with the medullary sinus where the nanoparticles seem to be located within the macrophages. (c) and (d) bright field images of the SLN corresponding to (a) respectively (b) which show the orientation and anatomy.